Summit Therapeutics
Executive Summary
Summit Therapeutics is a Miami-based biotech that pivoted from antibiotics to become Akeso's ex-China partner for ivonescimab, a PD-1/VEGF bispecific antibody. The company paid $500M upfront plus $5B in milestones for rights to what could be the first drug to beat Keytruda head-to-head in NSCLC. With a BLA filed and PDUFA date of November 2026, Summit represents a high-stakes bet on a potentially blockbuster oncology asset with clear BIOSECURE status.
Structure: Summit appears to be a straightforward US-domiciled public company (NASDAQ: SMMT) based in Miami with clear BIOSECURE status. The recent 10-K filing mentions VIE disclosures, suggesting some complexity in corporate structure that warrants review during due diligence, though the company itself is not designated under BIOSECURE.
Key People
| Name | Title | Education | Flags |
|---|---|---|---|
Mahkam Zanganeh | CEO | PharmD |
Ownership & Shareholder Structure
Akeso → Summit Therapeutics
Summit licensed ivonescimab ex-China ($5B+). PDUFA Nov 14, 2026.
Corporate Events
Summit Therapeutics 10-K Annual Report
10-K annual report filed with SEC. Contains corporate structure, VIE disclosures, and risk factors.
Summit files BLA for ivonescimab
Summit Therapeutics filed BLA with FDA for ivonescimab (Akeso's PD-1/VEGF bispecific) in NSCLC. PDUFA date Nov 14, 2026. If approved, first drug to beat Keytruda head-to-head.
BIOSECURE Risk
Company has clear BIOSECURE status and is not designated under BCC categories, indicating minimal direct exposure to BIOSECURE restrictions
Key Exposures:
- •VIE structure disclosures mentioned in 10-K may indicate indirect Chinese exposure
- •Relationship with Chinese partner Akeso could create supply chain dependencies
Mitigation: Company maintains clear BIOSECURE status, but VIE disclosures suggest ongoing monitoring needed
BD Intelligence
Therapeutic Areas:
Recent Deals: Major in-licensing deal with Akeso for ivonescimab ($500M upfront + $5B milestones) demonstrates significant deal execution capability and appetite for large transactions
Approach: Approach as a potential out-licensing partner given their proven ability to execute large deals and successful pivot strategy. Focus on late-stage oncology assets that complement ivonescimab.
Red Flags
- ⚠VIE structure disclosures in 10-K require investigation to understand potential Chinese regulatory exposure
- ⚠Company appears to be a one-asset story with significant dependence on ivonescimab success
- ⚠High milestone obligations to Akeso may limit financial flexibility for additional deals
Quick Facts
- Key People
- 1
- Subsidiaries
- 0
- CDMO/CRO Subs
- 0
- Genomics Subs
- 0
- Direct BIOSECURE
- 0
- Corp Events
- 2
- Gov-Connected
- 0
- Clinical Trials
- 0
- Publications
- 0
- Drug Molecules
- 0
- Relationships
- 1
Sources & Methodology
Clinical trials data: ClinicalTrials.gov API v2 (0 trials linked to this entity)
SEC BIOSECURE filings: EDGAR EFTS full-text search (850+ filings from 230 companies)
Publications: Europe PMC API (0 publications indexed)
Drug molecules: ChEMBL database (European Bioinformatics Institute)
Financial data: East Money (东方财富) datacenter API / CNINFO (巨潮资讯网)
Corporate structure: Company official filings, HKEX/SSE/SZSE disclosures
Executive profiles: Company official biographies, SEC filings, LinkedIn (where verified)
Data is collected from public sources and updated weekly. Corporate intelligence is verified by a native Mandarin-speaking analyst against Chinese-language primary sources including Tianyancha (天眼查), GSXT (国家企业信用信息公示系统), and CNINFO (巨潮资讯网). This is not financial or legal advice.